



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

**Public Declaration of Interests and Confidentiality Undertaking of
European Medicines Agency (EMA),
Scientific Committee members and experts**

Public declaration of interests

I, **Marco Greco**

Organisation/Company: European Patients' Forum

Country: Belgium

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

No Interest Declared

2.7 Grant / Funding to organisation /institution

Company	Subject Matter
Abbvie	45.000 workplan
Alexion	20.000 Stypa and Digital Health
AMGEN	40.000 Workplan and STYPA
Baxter	10.000 Capacity Building
Bayer	10.000 Project development
Biogen	15.000 Capacity Building Programme
BMS	75000 Workplan
Celgene	15.000 workplan
CSL	10.000 Workplan
Edwards Lifesciences	25000 Workplan
EFPIA	7.500 Incentives Workshop
Eli Lilly	15.000 Worplan
ENHA	10.000 workplan
Gilead	34.034 Workplan
Grunenthal	10.000 Workplan
GSK	100.000 Workplan and Capacity Building Program
Janssen	60.000 Workplan
Kyowakirin	10.000 Capacity Building Programme
MNI	20.000 Nutrition Initiative
Medicines for Europe	27500 Incentives Workshop and Workplan
Merck	30.000 Capacity Building and Digital Health
Microsoft	30.000 Digital Health
MSD	100.000 Workplan and EU Elections Campaing Project
Novartis	102.545 Workplan and Capacity Building Programme
Novo Nordisk	30.000 STYPA
PFIZER	50.000 Workplan
Roche	50.000 Workplan
Sanofi Aventis	50.000 Workplan
Servier	15.000 Workplan
Shire	15.000 Workplan and STYPA
Takeda	40.000 Workplan
UCB	30.000 Workplan
Vaccines Europe	75.000 Vaccines Initiative
Vertex	50.000 STYPA and Capacity Building
EUPATI (BAYER, NOVO NORDISK, ABBVIE, VFA, ASTRA ZENECA, UCB, AMGEN, BOEHRINGER, INGELHEIM, GSK, JANSSEN, NOVARTIS FARMA ITALY, NOVARTIS PHARMA AG, PFIZER, ROCHE, TAKEDA)	370.000 EUPATI WORKPLAN
PARADIGM (LDUNBECK, VFA, PFIZER)	58.000 PARADIGM WORKPLAN

2.8 Close family member interest

No interest declared

2.9 Any other interests or facts

I'm a volunteer and actually President of the board of the European Patients' Forum. EPF receives its funding from a diversified range of sources: membership fees; project funding from the European Commission; unrestricted grants from commercial companies; and (since 2012) a core operating grant from the European Commission. details of EPF's funders, funding arrangements and accounts are available on its website: <http://www.eu-patient.eu/About-EPF/Transparency/>

2014_Took part in an event organized by Takeda about Vedolizumab. Participation fee and reimbursement were provided to EFCCA (my previous affiliation) directly.

CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Marco Greco
Date:	2020-03-25

For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template

